Prenetics Global Limited

Prenetics Global Limited is a health sciences company dedicated to advancing consumer health through diagnostics and genetic testing. Founded in 2014, the company's mission is to redefine the future of health and longevity by making prevention, diagnostics, and personalized care accessible globally. Prenetics maintains dual headquarters in Hong Kong and Charlotte, North Carolina, USA.

The company operates primarily through two segments: Prevention and Diagnostics. Its Prevention segment includes CircleDNA, a consumer genetic testing brand that utilizes next-generation sequencing to provide comprehensive insights into health, wellness, and genetic predispositions. Another key offering in this segment is IM8, a health and wellness brand focused on supplements. The Diagnostics segment provides precision oncology testing services, featuring products like ACTOnco for comprehensive cancer testing and ACTHRD for assessing homologous recombination deficiency status.

In recent developments, Prenetics' IM8 brand, co-founded with David Beckham and endorsed by prominent athletes, has achieved rapid growth, reaching over $100 million in annual recurring revenue within 11 months of its launch. The company has also undertaken strategic portfolio optimization, including the divestiture of its ACT Genomics and Insighta businesses for significant proceeds, and the Europa sports nutrition distribution business. Prenetics, which became the first Hong Kong unicorn to list on Nasdaq in May 2022, has authorized a $40 million share repurchase program and maintains a Bitcoin treasury strategy.